Mechanism
MOTS-c is unusual: it is not encoded in the cell nucleus but within a short open reading frame in the mitochondrial genome. It behaves like a stress-responsive metabolic signal, and much of what is known comes from cell and animal work rather than human trials.
| Mechanism | Detail |
|---|---|
| AMPK activation | MOTS-c engages the AMPK pathway — a central energy sensor — which in animal models improves glucose uptake and shifts cells toward fuel-burning rather than fuel-storing programs. |
| Nuclear translocation | Under metabolic stress, MOTS-c moves into the nucleus and influences gene expression — atypical for a mitochondrial peptide. Well documented in cells; human relevance still being characterized. |
| Glucose handling | In rodent studies MOTS-c increased glucose utilization and reduced diet-induced insulin resistance. Whether injected MOTS-c reproduces this in humans has not been shown. |
| Exercise-linked signal | In humans, endogenous MOTS-c rises in muscle and blood with exercise, then returns to baseline — which is why it is framed as an “exercise-mimetic.” That describes natural physiology, not proof that supplementing it mimics exercise. |
Evidence Summary
The MOTS-c literature is preclinical-dominant. Animal and mechanistic findings are genuinely interesting; the human side is largely observational, and interventional data on administered MOTS-c is essentially absent.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Metabolic / obesity | Improved metabolic homeostasis | Preclinical | Foundational 2015 work; strong effect in diet-induced obese mice, not yet human-confirmed. |
| Exercise capacity | Increased running capacity | Preclinical | Widely cited across young, middle-aged and old mice; the headline is a mouse result. |
| Muscle bioenergetics | Improved mitochondrial efficiency | Preclinical | PGC-1α/AMPK-dependent; mechanistic support for the AMPK story. |
| Human exercise physiology | Exercise raises endogenous MOTS-c | Human (observational) | Confirms MOTS-c is a real human signal — does not test supplementation. |
| Aging / longevity | Proposed metabolic regulator | Preclinical | Hypothesis-generating; no human longevity data. |
| Human clinical trials | No completed interventional trials | Very limited | Nearly all human use is anecdotal and ahead of the evidence. |
Divergence — What This Means
Community practice runs well ahead of the science.
MOTS-c is a clear example of the gap between an exciting animal literature and thin human evidence. Compelling mouse results — fat loss, insulin sensitivity, dramatic endurance gains — get carried directly into human injection protocols that no trial has validated.
Community doses are extrapolated from rodent studies that, by the researchers’ own framing, do not translate linearly to humans. Cycling schemes (for example 5-days-on / 2-off) are built on reasonable-sounding theory rather than outcome data. Treat everything below as a description of what people do, not a recommendation.
Community doses are extrapolated from rodent studies that, by the researchers’ own framing, do not translate linearly to humans. Cycling schemes (for example 5-days-on / 2-off) are built on reasonable-sounding theory rather than outcome data. Treat everything below as a description of what people do, not a recommendation.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Typical reported dose
~0.5–1 mg
per day, community/anecdotal
Higher-dose reports
up to ~5 mg/day
extrapolated from animal work; unsupported
Common schedule
5 on / 2 off
often run in ~8-week blocks
Route
Subcutaneous
reconstituted; not orally active
Figures are community and anecdotal only, gathered from forums and vendor guides — not medical advice, not established dosing, and not for human use. No trial has established a safe or effective human dose. Sold strictly research-use-only.
Safety Profile
Human safety data for administered MOTS-c is minimal because controlled human trials are lacking. What follows is drawn from limited animal work and self-reported community experience, both of which have obvious limits.
Animal / preclinical — signals observed
Injection-site reactions (redness, irritation) reported anecdotally
Reports of transient fatigue or lightheadedness
Described as well-tolerated at low doses in short-term self-report — low-quality evidence
What is not known (human)
No established human safety profile from controlled trials
Long-term effects of chronic AMPK activation in humans are unstudied
Interactions with glucose-lowering or diabetes medications are uncharacterized
Effects in pregnancy or with existing metabolic disease are unknown
Purity and identity vary widely across RUO suppliers
This is not medical advice. MOTS-c is sold research-use-only and is not approved for human use. Anyone considering it should recognize the human evidence base is very early.
Regulatory Status — Updated July 2026
Recommended for the 503A list — narrowly
On July 24, 2026 (Day 2 of the PCAC meeting), the Pharmacy Compounding Advisory Committee voted 7–5–2 to recommend MOTS-c for the FDA’s 503A bulk drug substances list. It was a closer margin than the Day 1 peptides, reflecting genuine debate about the strength of the human evidence. The vote is advisory only — it does not by itself authorize compounding, and formal FDA rulemaking is still pending. For now MOTS-c continues to be sold research-use-only. Track current status →
Where to Source
Source research-grade MOTS-c
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source MOTS-c.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
On July 24, 2026, the committee voted 7–5–2 to recommend MOTS-c for the 503A bulks list. The split vote signals real uncertainty. It is a recommendation to the FDA, not a final decision, and rulemaking is still pending.
No. The impressive results — fat loss, insulin sensitivity, big endurance gains — come from animal studies. In humans, the main finding is that exercise naturally raises MOTS-c; there are no completed interventional trials showing that injecting it produces those benefits.
Because endogenous MOTS-c rises with exercise and its animal effects overlap with training adaptations. That is an analogy based on physiology and mouse data, not evidence that supplementing MOTS-c substitutes for exercise in people.
Community protocols commonly report ~0.5–1 mg per day subcutaneously, often 5-on / 2-off, with some using higher doses extrapolated from animal studies. None of this is validated by human trials, and it is not medical advice.
Compare MOTS-c